Drugs

Drugs is a monthly peer-reviewed medical journal published by Adis International, part of Springer Nature, covering drug therapy and clinical pharmacology with print ISSN 0012-6667 and online ISSN 1179-1950, and its 2025 Journal Impact Factor is 14.7（Drugs）是由（Adis International）出版的同行评审医学月刊，隶属（Springer Nature），涵盖药物治疗与临床药理学，印刷 ISSN 为 0012-6667，在线 ISSN 为 1179-1950，2025 年影响因子为 14.7。

Scope

• It publishes reviews and original clinical research on drugs and therapeutics to support clinical decision-making该刊发表药物与治疗学方面的综述与原创临床研究，以支持临床决策。
• It promotes optimum pharmacotherapy and covers the full spectrum of new and established drug therapies in all disease areas该刊倡导最优药物治疗，覆盖所有疾病领域的新药与成熟药物疗法。
• Its Adis Drug Evaluations are definitive peer-reviewed reviews of newer and established drugs and their place in patient management其（Adis Drug Evaluations）是对新药与成熟药物及其在患者管理中定位的权威同行评审综述。
• It publishes First Approval reviews of drugs receiving a first global approval and original research on pivotal late-phase clinical trials该刊发表药物首次全球获批的（First Approval）综述以及关键性后期临床试验的原创研究。^[1]
• It provides detailed and objective analysis of pharmacy, pharmacotherapy and drug safety topics该刊提供涵盖药学、药物治疗与药物安全的详尽客观分析。
• As a hybrid journal it offers authors the option to publish accepted articles open access under a Creative Commons licence作为混合期刊，它为作者提供以（Creative Commons）许可开放获取发表接收文章的选择。

History

• Drugs was first published in 1971 by Adis Press and has become a leading source of drug evaluation and information（Drugs）由（Adis Press）于 1971 年首次出版，已成为药物评价与信息的重要来源。^[2]
• It is one of a family of Adis journals that also includes Drugs and Aging, Drug Safety and Clinical Drug Investigation它是（Adis）期刊群之一，该群体还包括（Drugs and Aging）、（Drug Safety）与（Clinical Drug Investigation）。
• The Adis journals were acquired by Springer Science+Business Media at the end of 2011, with integration completed by 2013（Adis）期刊于 2011 年底被（Springer Science+Business Media）收购，整合工作于 2013 年完成。
• The title passed more than 50 years of continuous publication and reached volume 86 by 2026该刊已连续出版五十余年，至 2026 年出至第 86 卷。
• Its Journal Impact Factor moved from 9.546 in 2021 to 11.431 in 2022, 14.4 in 2024 and 14.7 in 2025影响因子由 2021 年的 9.546 升至 2022 年的 11.431，2024 年为 14.4，2025 年为 14.7。
• In the 2025 Journal Citation Reports it is a Q1 title in both Toxicology and Pharmacology and Pharmacy on the Science Citation Index Expanded在 2025 年（Journal Citation Reports）中，它在毒理学以及药理学与药学类别均为（SCIE）的 Q1 期刊。^[3]

Editors

• The editor of Drugs is Sue Pochon of Adis International in Auckland, New Zealand（Drugs）的编辑为（Sue Pochon），供职于新西兰奥克兰的（Adis International）。
• The journal is supported by section editors including Esther Bulloch, Martin Chopra and Alison Fitches该刊由栏目编辑支持，包括（Esther Bulloch）、（Martin Chopra）与（Alison Fitches）。
• An international editorial board of clinicians and researchers guides the journal's content由临床医生与研究者组成的国际编委会指导该刊的内容。
• Dene Peters earlier served as editor-in-chief of Drugs as part of the Adis editorial team（Dene Peters）曾作为（Adis）编辑团队的一员担任（Drugs）主编。
• Drugs operates an in-house editorial model with a fast submission-to-first-decision time of about eight days该刊采用内部编辑模式，从投稿到首次决定约需八天。